期刊文献+

年轻多囊卵巢综合征患者发生子宫内膜样腺癌并透明细胞癌1例报告 被引量:1

Endometrial adenocarcinoma and clear cell carcinoma in a young woman with polycystic ovarian syndrome:a case report
下载PDF
导出
摘要 患者,26岁,未婚未育。主诉月经不调4年,阴道流血10 d,发现宫腔占位5 d。病理检查:中-低分化子宫内膜样腺癌。行腹腔镜下筋膜外全子宫及双附件切除术,术后诊断:子宫内膜样中低分化腺癌并透明细胞癌Ⅱ期,辅予以化疗,患者恢复可。年轻多囊卵巢综合症患者是发生子宫内膜癌的高危人群,而合并透明细胞癌者罕见,术前多科室综合评估、治疗方式的选择及预后分析是十分必要的,这也为今后的临床工作提供了经验。 A 26-year-old unmarried woman with irregular menstruation for 4 years was admitted for an intrauterine space-occupying mass. Pathological examination before surgery showed moderately to poorly differentiated endometrial adenocarcinoma. The patient underwent laparoscopically assisted epifascial panhysterectomy with bilateral salpingo-oophorectomy. Pathological examination of the surgical specimens reported moderately to poorly differentiated endometrial adenocarcinoma and stage II clear cell carcinoma. The patient then received chemotherapy and remained alive without evidence of recurrence. Young women with polycystic ovarian syndrome are at high risk of developing endometrial carcinoma, but concurrent clear cell carcinoma is rare. Careful evaluation before and after treatment are essential to improve the patients’prognosis.
出处 《南方医科大学学报》 CAS CSCD 北大核心 2016年第5期733-734,F0003,共3页 Journal of Southern Medical University
基金 广东省自然科学基金(2015A030313292) 广东省省级科技计划项目(2014A0202212188) 南方医科大学南方医院院长基金(2013B014)
关键词 多囊卵巢综合征 子宫内膜样腺癌 透明细胞癌 polycystic ovarian syndrome endometrial adenocarcinoma clear cell carcinoma
  • 相关文献

参考文献17

  • 1Morice P, Leary A, Creutzberg C, et al. Endometrial cancer [J]. Lancet, 2016, 387(123): 1094-108.
  • 2Setiawan VW, Yang HP, Pike MC, et al. Type I and II endometrialcancers: have they different risk factors[J]. J Clin Oncol, 2013, 31 (20): 2607-18.
  • 3Malpica A, Tornos C, Burke TW, et al. Low-stage clear-cell carcinoma of the endometrium [J]. Am J Surg Pathol, 1995, 19(7): 769-74.
  • 4Gadducci A, Cosio S, Spirito N, et al. Clear cell carcinoma of the endometrium: a biological and clinical enigma[J]. Anticancer Res, 2010, 30(4): 1327-34.
  • 5Hasegawa K, Nagao. S, Yasuda M, et al. Gynecologic cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the uterine corpus and cervix[J]. Int J Gynecol Cancer, 2014, 24(9 Suppl 3): S90-5.
  • 6Koh W, Greer BE, Abu-Rustum NR, et al. Uterine neoplasms [J]. J Natl Compr Canc Netw, 2014, 12(2): 248-80.
  • 7Maggino T, Zola P, Sartori E, et al. Clear cell endometrial cancer: a CTF multicentre Italian study[J]. Eur J Gynaecol Oncol, 2015, 36 (4): 428-31.
  • 8庞晓燕,张颐,郭科军.子宫内膜透明细胞癌的临床分析[J].中国医科大学学报,2009,38(12):921-923. 被引量:3
  • 9吴倩,李群.子宫内膜透明细胞癌的诊治进展[J].实用医学杂志,2014,30(8):1328-1330. 被引量:3
  • 10Hunn J, Tenney ME, Tergas AI, et al. Patterns and utility of routine surveillance in high grade endometrial cancer [J]. Gynecol Oncol, 2015, 137(3): 485-9.

二级参考文献23

  • 1詹娜,黎辉,王则胜,熊永炎.子宫内膜透明细胞癌的免疫组化研究[J].诊断病理学杂志,2006,13(2):85-88. 被引量:3
  • 2Mendivil A, Schuler KM, Gehrig PA, et al. Non-Endometrioid Ad-enocarcino-ma of the Uterine Corpus : A Review of Selected Histo-logical Subtypes [J]. Cancer Control, 2009,16 ( 1 ) :46-52.
  • 3Viswanathan AN, Macklin EA, Berkowitz R, et al. The importance of chemotherapy and radiation in uterine papillary serous carcino-ma [J]. Gy- necol Oncol, 2011,123 ( 3 ) : 542-547.
  • 4Oluwole Fadare, MD and Sharon X. Liang, MD, PhDw Diagnostic Utility of Hepatocyte Nuclear Factor 1-Beta Im- munoreactivity in Endometrial Carcino- Lack of Specificity For Endome- trial Clear Cell Carcinoma [J]. Appl Immunohistochem Mol Morphol, 2012; 20(6) :580-587.
  • 5Uwe S, Heidi F, Marco P, et al. Epige- netic regulation of L1CAM in endometrial carcinoma: comparison to cancer-testis (CT-X) antigens [J]. BMC Cancer, 2013,13:156.
  • 6Wild P J, Ikenberg K, Fuchs TJ, et al. p53 suppresses type II endometrial car- cinomas in mice and governs endometri- a! tumour aggressiveness in humans [J]. EMBO Mol Med, 2012,4 (8):808- 824.
  • 7Fadare O, Gwin K, Desouki MM, et al. The clinicopathologic significance of p53 and BAF-250a (ARID1A) expres- sion in clear cell carcinoma of the en- dometrium [J]. Mod Pathol, 2013,26 (8): 1101-1110.
  • 8Session DR, Lee GS, Choi J, et al. Expression of cyclin E in gynecologic malignanciesJ [J]. Cynecol oncolo, 1999,72( 1 ) .. 32-37.
  • 9Fadare O, Renshaw IL, Liang SX. Does the Loss of ARID1A (BAF-250a) Expression in Endometrial Clear Cell Carcinomas Have Any Clinicopathologic Significance? A Pilot Assessment [Jl. J Cancer, 2012,3 : 129-136.
  • 10Kawano Y, Kypta R. Secreted antago- nist s of the Wnt signalling pathway [J]. Jcellsci, 2003,116(13) :2627.

共引文献10

同被引文献13

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部